{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:04:08Z","timestamp":1789718648617,"version":"4.0.1"},"reference-count":161,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>The advent of immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T-cell (CAR-T) therapies has revolutionized oncology but is increasingly associated with severe cardiovascular immune-related adverse events (irAEs). This narrative review comprehensively examines the epidemiology, pathophysiologic mechanisms, biomarkers, advanced imaging, and management strategies for immunotherapy-associated cardiovascular toxicities. ICI-associated myocarditis is a rare but potentially fatal complication occurring early in therapy, particularly with combination regimens, while the broader cardiovascular spectrum also encompasses pericarditis, arrhythmias, heart failure, and accelerated atherosclerosis. Mechanistically, preclinical data suggest that ICI-associated myocarditis is hypothesized to be mediated by autoreactive CD8+ T-cell cross-reactivity against shared cardiac antigens, macrophage expansion, and inflammatory cytokine signaling, whereas CAR-T cardiovascular toxicity appears to contribute primarily secondary to systemic cytokine release syndrome (CRS). For early detection and risk stratification, high-sensitivity cardiac troponin remains the foundational biomarker, complemented by advanced multimodal imaging such as global longitudinal strain (GLS) echocardiography, cardiac magnetic resonance (CMR), and emerging molecular positron emission tomography (PET). High-dose systemic corticosteroids remain the first-line intervention for symptomatic ICI-associated myocarditis, with targeted therapies like abatacept and ruxolitinib showing promise for steroid-refractory cases. Ultimately, proactive risk factor assessment and multidisciplinary cardio-oncology surveillance are imperative to mitigate acute toxicities and long-term atherosclerotic risks, ensuring optimal patient outcomes.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1891563","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:42:33Z","timestamp":1789717353000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancing precision cardio-oncology: multimodal surveillance and stratified management of immunotherapy-induced cardiovascular toxicity"],"prefix":"10.3389","volume":"13","author":[{"given":"Bihan","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Cardiac Surgery, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41568-024-00715-5","article-title":"Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart","volume":"24","author":"Munir","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e075859","DOI":"10.1136\/bmj-2023-075859","article-title":"Cardiovascular toxicity of immune therapies for cancer","volume":"385","author":"Palaskas","year":"2024","journal-title":"Br Med J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/ejhf.3340","article-title":"Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the heart failure association (HFA) of the ESC and the ESC council of cardio-oncology","volume":"26","author":"Tocchetti","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"B4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccl.2019.07.008","article-title":"Cardiotoxicity of immune therapy","volume":"37","author":"Ganatra","year":"2019","journal-title":"Cardiol Clin"},{"key":"B5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s11936-020-00867-1","article-title":"Cardiotoxicity of contemporary anticancer immunotherapy","volume":"22","author":"Dal'bo","year":"2020","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-020-0897-9","article-title":"Immune-Related adverse events (irAEs): diagnosis, management, and clinical pearls","volume":"22","author":"Darnell","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1340373","DOI":"10.3389\/fimmu.2024.1340373","article-title":"Immune checkpoint inhibitors associated cardiovascular immune-related adverse events","volume":"15","author":"Jo","year":"2024","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/978-3-030-79308-1_15","article-title":"Immune checkpoint inhibitor (ICI)-related cardiotoxicity","volume":"1342","author":"Zarifa","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1161\/CIRCULATIONAHA.124.065473","article-title":"Cardio-oncology: a new clinical frontier and novel platform for cardiovascular investigation","volume":"150","author":"Moslehi","year":"2024","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/978-3-031-33602-7_12","article-title":"New concepts in cardio-oncology","volume":"188","author":"Zagami","year":"2023","journal-title":"Cancer Treat Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11936-019-0731-6","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"21","author":"Zhang","year":"2019","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/jamaoncol.2025.4543","article-title":"Immune checkpoint inhibitor-associated cardiovascular toxic effects: international cardio-oncology society position statement","volume":"12","author":"Herrmann","year":"2026","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","article-title":"Immune checkpoint inhibitor-associated myocarditis","volume":"23","author":"Ganatra","year":"2018","journal-title":"Oncologist"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"113559","DOI":"10.1016\/j.intimp.2024.113559","article-title":"Insight of immune checkpoint inhibitor related myocarditis","volume":"143","author":"Pi","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11912-021-01070-6","article-title":"Cardiotoxicity of immune checkpoint Inhibitors","volume":"23","author":"Patel","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1002\/ehf2.15281","article-title":"Immune checkpoint inhibitors and cardiovascular adverse events","volume":"12","author":"De Perna","year":"2025","journal-title":"ESC Heart Fail"},{"key":"B18","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s11912-023-01411-7","article-title":"Cardiovascular effects of immune checkpoint inhibitors: more than just myocarditis","volume":"25","author":"Inno","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3390\/jcm11030865","article-title":"The potential cardiotoxicity of immune checkpoint inhibitors","volume":"11","author":"Nardi Agmon","year":"2022","journal-title":"J Clin Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11912-021-01068-0","article-title":"Cardiovascular toxicities of CAR T-cell therapy","volume":"23","author":"Patel","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e230622206353","DOI":"10.2174\/1573403X18666220623152350","article-title":"Cardiovascular toxicities with chimeric antigen receptor T-cell therapy","volume":"19","author":"Gill","year":"2023","journal-title":"Curr Cardiol Rev"},{"key":"B22","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1111\/ejh.14289","article-title":"The cardiotoxic effects of CAR-T cell therapy: an updated systematic review and meta-analysis","volume":"113","author":"Mazetto","year":"2024","journal-title":"Eur J Haematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.3390\/cancers14184494","article-title":"Pathophysiology of immune checkpoint inhibitor-induced myocarditis","volume":"14","author":"Jim\u00e9nez-Alejandre","year":"2022","journal-title":"Cancers Basel"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1130438","DOI":"10.3389\/fimmu.2023.1130438","article-title":"Advances in immune checkpoint inhibitors induced-cardiotoxicity","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.currproblcancer.2018.07.002","article-title":"Cardiotoxicities associated with immune checkpoint inhibitors","volume":"42","author":"Yang","year":"2018","journal-title":"Curr Probl Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"6282","DOI":"10.1182\/bloodadvances.2024013849","article-title":"Cardiovascular toxicities associated with novel cellular immune therapies","volume":"8","author":"Munir","year":"2024","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","article-title":"Cardiomuscular biomarkers in the diagnosis and prognostication of immune checkpoint inhibitor myocarditis","volume":"148","author":"Lehmann","year":"2023","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the cardio-oncology study group of the heart failure association and the cardio-oncology council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0314555","DOI":"10.1371\/journal.pone.0314555","article-title":"Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors","volume":"19","author":"Kwan","year":"2024","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11912-023-01414-4","article-title":"Risk factors for immune checkpoint inhibitor-mediated cardiovascular toxicities","volume":"25","author":"Yousif","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1188\/22.CJON.54-60","article-title":"Immune checkpoint inhibitor-related myocarditis: recognition, surveillance, and management","volume":"26","author":"Kuhnly","year":"2022","journal-title":"Clin J Oncol Nurs"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00392-024-02462-x","article-title":"Adverse myocardial and vascular side effects of immune checkpoint inhibitors: a prospective multimodal cardiovascular assessment","volume":"113","author":"Mirabel","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e032620","DOI":"10.1161\/JAHA.123.032620","article-title":"Immune checkpoint inhibitors and cardiotoxicity: a comparative meta-analysis of observational studies and randomized controlled trials","volume":"13","author":"Sharma","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1347140","DOI":"10.3389\/fonc.2024.1347140","article-title":"Immunotherapy-associated cardiovascular toxicities: insights from preclinical and clinical studies","volume":"14","author":"Kong","year":"2024","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"oyaf285","DOI":"10.1093\/oncolo\/oyaf285","article-title":"Immune checkpoint inhibitor-related myocarditis: a comprehensive analysis of clinical manifestations and prognostic factors","volume":"30","author":"Fan","year":"2025","journal-title":"Oncologist"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1186\/s12885-025-14668-x","article-title":"Immune checkpoint inhibitor-associated myocarditis and pericarditis: a pharmacovigilance study based on the FAERS database","volume":"25","author":"Yao","year":"2025","journal-title":"BMC Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review","volume":"6","author":"Lehmann","year":"2021","journal-title":"JAMA Cardiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jaccao.2025.01.020","article-title":"Immune checkpoint inhibitor myocarditis and left ventricular systolic dysfunction","volume":"7","author":"Chen","year":"2025","journal-title":"JACC CardioOncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/COC.0000000000001166","article-title":"Cardiovascular risk profile of nivolumab anti-cancer therapy: a review of current literature","volume":"48","author":"Qureshi","year":"2025","journal-title":"Am J Clin Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1136\/heartjnl-2020-318083","article-title":"Cardiotoxicities of novel cancer immunotherapies","volume":"107","author":"Stein-Merlob","year":"2021","journal-title":"Heart"},{"key":"B43","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e70154","DOI":"10.1002\/clc.70154","article-title":"Immune checkpoint inhibitor-related myocarditis: a single center observational registry","volume":"48","author":"Alexander","year":"2025","journal-title":"Clin Cardiol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e7233","DOI":"10.1002\/cam4.7233","article-title":"Cardiovascular adverse events associated with immune checkpoint inhibitors: a retrospective multicenter cohort study","volume":"13","author":"Zheng","year":"2024","journal-title":"Cancer Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/imr.13240","article-title":"Mediators and mechanisms of immune checkpoint inhibitor-associated myocarditis: insights from mouse and human","volume":"318","author":"Gong","year":"2023","journal-title":"Immunol Rev"},{"key":"B47","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.yjmcc.2021.07.006","article-title":"Immune checkpoint inhibitor cardiotoxicity: breaking barriers in the cardiovascular immune landscape","volume":"160","author":"Zhu","year":"2021","journal-title":"J Mol Cell Cardiol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11912-020-00925-8","article-title":"New insights into mechanisms of immune checkpoint inhibitor-induced cardiovascular toxicity","volume":"22","author":"Khunger","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B49","doi-asserted-by":"publisher","first-page":"102282","DOI":"10.1016\/j.ctrv.2021.102282","article-title":"Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors","volume":"100","author":"Arangalage","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B50","doi-asserted-by":"publisher","first-page":"111611","DOI":"10.1016\/j.celrep.2022.111611","article-title":"Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis","volume":"41","author":"Won","year":"2022","journal-title":"Cell Rep"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e20251717","DOI":"10.1084\/jem.20251717","article-title":"Immune checkpoint inhibitor-induced myocarditis is dependent on CD8 T cell-derived TNF and TNFR2 signaling","volume":"223","author":"Warrick","year":"2026","journal-title":"J Exp Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"721333","DOI":"10.3389\/fcvm.2021.721333","article-title":"Immune checkpoint inhibitors mediated lymphocytic and giant cell myocarditis: uncovering etiological mechanisms","volume":"8","author":"Rikhi","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00395-024-01070-0","article-title":"Preclinical models of cardiotoxicity from immune checkpoint inhibitor therapy","volume":"120","author":"Buehning","year":"2025","journal-title":"Basic Res Cardiol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3390\/biomedicines11010107","article-title":"Immunopathogenesis of immune checkpoint inhibitor induced myocarditis: insights from experimental models and treatment implications","volume":"11","author":"Wong","year":"2023","journal-title":"Biomedicines"},{"key":"B55","author":"Ma","year":"2023"},{"key":"B56","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40959-023-00166-1","article-title":"Clinicopathological classification of immune checkpoint inhibitor-associated myocarditis: possible refinement by measuring macrophage abundance","volume":"9","author":"Jimenez","year":"2023","journal-title":"Cardiooncology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00395-024-01068-8","article-title":"Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors","volume":"120","author":"Gergely","year":"2025","journal-title":"Basic Res Cardiol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1762011","DOI":"10.3389\/fphar.2026.1762011","article-title":"Immunotherapy-related cardiovascular toxicity: from mechanisms to management","volume":"17","author":"Xiao","year":"2026","journal-title":"Front Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/bph.15984","article-title":"Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment","volume":"180","author":"Gergely","year":"2023","journal-title":"Br J Pharmacol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1232269","DOI":"10.3389\/fcvm.2024.1232269","article-title":"Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1\u03b2 and interleukin-6: biochemical implications in cardio-immuno-oncology","volume":"11","author":"Quagliariello","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"eabo1981","DOI":"10.1126\/scitranslmed.abo1981","article-title":"Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis","volume":"14","author":"Zhang","year":"2022","journal-title":"Sci Transl Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1002\/ehf2.14614","article-title":"Previous cardiovascular injury is a prerequisite for immune checkpoint inhibitor-associated lethal myocarditis in mice","volume":"11","author":"Rubio-Infante","year":"2024","journal-title":"ESC Heart Fail"},{"key":"B63","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jaccao.2026.03.003","article-title":"PD-L1 in ICI myocarditis: when the immune brake fails","volume":"8","author":"Chen","year":"2026","journal-title":"JACC CardioOncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41569-026-01265-z","article-title":"Cardiotoxicity of T cell immunotherapies","volume":"23","author":"Raddatz","year":"2026","journal-title":"Nat Rev Cardiol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"8242","DOI":"10.3390\/ijms23158242","article-title":"Cardiotoxicity of chimeric antigen receptor T-cell (CAR-T) therapy: pathophysiology, clinical implications, and echocardiographic assessment","volume":"23","author":"Nenna","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B66","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaccao.2023.07.009","article-title":"Incidence of MACE in patients treated with CAR-T cell therapy: a prospective study","volume":"5","author":"Lefebvre","year":"2023","journal-title":"JACC CardioOncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s11886-023-01915-5","article-title":"Role of biomarkers in the management of immune-checkpoint inhibitor-related myocarditis","volume":"25","author":"Vasbinder","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"B68","doi-asserted-by":"publisher","first-page":"100216","DOI":"10.1016\/j.esmoop.2021.100216","article-title":"Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy","volume":"6","author":"Delombaerde","year":"2021","journal-title":"ESMO Open"},{"key":"B69","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.3390\/cancers13215426","article-title":"Role of cardiac biomarkers in cancer patients","volume":"13","author":"Semeraro","year":"2021","journal-title":"Cancers Basel"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1350585","DOI":"10.3389\/fcvm.2024.1350585","article-title":"Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach","volume":"11","author":"Murtagh","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/eurheartj\/ehaf315","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score","volume":"47","author":"Power","year":"2026","journal-title":"Eur Heart J"},{"key":"B72","author":"Power","year":"2024"},{"key":"B73","doi-asserted-by":"publisher","first-page":"101375","DOI":"10.1016\/j.jacadv.2024.101375","article-title":"Elevations of cardiac troponin in patients receiving immune checkpoint inhibitors: data from a prospective study","volume":"3","author":"van Den Berg","year":"2024","journal-title":"JACC Adv"},{"key":"B74","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jaccao.2025.06.009","article-title":"Cardiac troponin screening and clinical outcomes in patients receiving immunotherapy","volume":"7","author":"Cheng","year":"2025","journal-title":"JACC CardioOncol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"oyaf147","DOI":"10.1093\/oncolo\/oyaf147","article-title":"The predictive value of serial troponin measurements in patients treated with immune checkpoint inhibitors","volume":"30","author":"Gvili Perelman","year":"2025","journal-title":"Oncologist"},{"key":"B76","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00392-022-02118-8","article-title":"The predictive value of high sensitivity troponin measurements in patients treated with immune checkpoint inhibitors","volume":"112","author":"Waissengein","year":"2023","journal-title":"Clin Res Cardiol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/eurheartj\/ehad117","article-title":"Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients","volume":"44","author":"Mahmood","year":"2023","journal-title":"Eur Heart J"},{"key":"B78","doi-asserted-by":"publisher","first-page":"102022","DOI":"10.1016\/j.jacadv.2025.102022","article-title":"Prognostic value of biomarkers in cancer patients treated with immune checkpoint inhibitor therapy","volume":"4","author":"Mann","year":"2025","journal-title":"JACC Adv"},{"key":"B79","doi-asserted-by":"publisher","first-page":"625","DOI":"10.3390\/ph16040625","article-title":"Extensive CArdioVAscular characterization and follow-up of patients receiving immune checkpoint inhibitors: a prospective multicenter study","volume":"16","author":"Delombaerde","year":"2023","journal-title":"Pharm Basel"},{"key":"B80","doi-asserted-by":"publisher","first-page":"106509","DOI":"10.3748\/wjg.v31.i26.106509","article-title":"Risk factors and diagnostic biomarkers for asymptomatic immune checkpoint inhibitor-related myocarditis in patients with esophageal cancer after immunotherapy","volume":"31","author":"Liu","year":"2025","journal-title":"World J Gastroenterol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"e20250047","DOI":"10.36660\/abc.20250047i","article-title":"Prognostic value of troponin to lymphocyte ratio in patients with immune checkpoint inhibitor-associated myocarditis","volume":"122","author":"Chen","year":"2025","journal-title":"Arq Bras Cardiol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s11033-025-11095-w","article-title":"Cytokine profiling of patients with immune checkpoint inhibitor-associated myocarditis: a pilot study","volume":"52","author":"Li","year":"2025","journal-title":"Mol Biol Rep"},{"key":"B83","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/diseases12050088","article-title":"Elevated IL-6 and tumor necrosis factor-\u03b1 in immune checkpoint inhibitor myocarditis","volume":"12","author":"Ali","year":"2024","journal-title":"Diseases"},{"key":"B84","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40959-024-00289-z","article-title":"Clonal hematopoiesis of indeterminate potential is associated with increased risk of immune checkpoint inhibitor myocarditis in a prospective study of a cardio-oncology cohort","volume":"10","author":"Jaber Chehayeb","year":"2024","journal-title":"Cardiooncology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1139\/bcb-2025-0170","article-title":"Identification of features and differences in PD-1 inhibitor-associated myocarditis and acute myocardial infarction using proteomic analysis: a clinical and preclinical study","volume":"103","author":"Luo","year":"2025","journal-title":"Biochem Cell Biol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"614997","DOI":"10.3389\/fcvm.2021.614997","article-title":"Early detection of checkpoint inhibitor-associated myocarditis using (68)Ga-FAPI PET\/CT","volume":"8","author":"Finke","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"e003594","DOI":"10.1136\/jitc-2021-003594","article-title":"(68)Ga-DOTATOC PET\/CT to detect immune checkpoint inhibitor-related myocarditis","volume":"9","author":"Boughdad","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B88","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.3390\/jcm14082850","article-title":"Multimodal imaging of immune checkpoint inhibitor myocarditis","volume":"14","author":"Patel","year":"2025","journal-title":"J Clin Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/ijc.34169","article-title":"Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis","volume":"151","author":"Cau","year":"2022","journal-title":"Int J Cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"e70115","DOI":"10.1111\/echo.70115","article-title":"Multimodality imaging and immune-related adverse events during immune checkpoint inhibitors treatment: where do we stand?","volume":"42","author":"Crosio","year":"2025","journal-title":"Echocardiography"},{"key":"B91","first-page":"3548","article-title":"Cardiac imaging techniques for the assessment of immune checkpoint inhibitor-induced cardiotoxicity and their potential clinical applications","volume":"12","author":"Li","year":"2022","journal-title":"Am J Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.jaccao.2022.10.007","article-title":"Longitudinal strain and troponin I elevation in patients undergoing immune checkpoint inhibitor therapy","volume":"4","author":"Tamura","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3533","DOI":"10.1002\/ehf2.14094","article-title":"Right ventricular and atrial strain in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy","volume":"9","author":"Pohl","year":"2022","journal-title":"ESC Heart Fail"},{"key":"B94","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12574-023-00621-z","article-title":"Role of echocardiography in patients treated with immune checkpoints inhibitors","volume":"21","author":"Tanabe","year":"2023","journal-title":"J Echocardiogr"},{"key":"B95","doi-asserted-by":"publisher","first-page":"640985","DOI":"10.3389\/fonc.2021.640985","article-title":"Role of cardiac imaging in the diagnosis of immune checkpoints inhibitors related myocarditis","volume":"11","author":"Ederhy","year":"2021","journal-title":"Front Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1148\/radiol.211765","article-title":"Cardiac MRI features and prognostic value in immune checkpoint inhibitor-induced myocarditis","volume":"303","author":"Cadour","year":"2022","journal-title":"Radiology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"101581","DOI":"10.1016\/j.ijcha.2024.101581","article-title":"Cardiac magnetic resonance imaging in patients with suspected myocarditis from immune checkpoint inhibitor therapy - A real-world observational study","volume":"56","author":"Lerchner","year":"2025","journal-title":"Int J Cardiol Heart Vasc"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e010568","DOI":"10.1136\/jitc-2024-010568","article-title":"Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events","volume":"13","author":"Losurdo","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B99","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40959-022-00130-5","article-title":"Cardiotoxicity risk factors with immune checkpoint inhibitors","volume":"8","author":"Brumberger","year":"2022","journal-title":"Cardiooncology"},{"key":"B100","doi-asserted-by":"publisher","first-page":"e70087","DOI":"10.1111\/anec.70087","article-title":"Cardiac adverse events in patients receiving immune checkpoint inhibitors in the adjuvant setting: an FDA pooled analysis","volume":"30","author":"Dilawari","year":"2025","journal-title":"Ann Noninvasive Electrocardiol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1062858","DOI":"10.3389\/fcvm.2022.1062858","article-title":"Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors","volume":"9","author":"Torrente","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.hlc.2023.10.008","article-title":"Atherosclerotic cardiovascular events in cancer patients treated with immune checkpoint inhibitors: a retrospective cohort study","volume":"33","author":"Tan","year":"2024","journal-title":"Heart Lung Circ"},{"key":"B103","doi-asserted-by":"publisher","first-page":"115404","DOI":"10.1016\/j.ejca.2025.115404","article-title":"Cardiological adverse events in hepatocellular carcinoma patients receiving immunotherapy: influence of comorbidities and clinical outcomes","volume":"221","author":"Fortuny","year":"2025","journal-title":"Eur J Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s12672-024-01416-z","article-title":"Thromboembolism during immune checkpoint inhibitor therapy: frequency and risk factors","volume":"15","author":"Ide","year":"2024","journal-title":"Discov Oncol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1200\/JCO.21.01806","article-title":"Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: data from the phase III JAVELIN renal 101 trial","volume":"40","author":"Rini","year":"2022","journal-title":"J Clin Oncol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"e14370","DOI":"10.1111\/eci.14370","article-title":"Applications, challenges and future directions of artificial intelligence in cardio-oncology","volume":"55","author":"Francesco","year":"2025","journal-title":"Eur J Clin Invest"},{"key":"B107","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3390\/diagnostics16030488","article-title":"Artificial intelligence and the expanding universe of cardio-oncology: beyond detection toward prediction and prevention of therapy-related cardiotoxicity\u2014a comprehensive review","volume":"16","author":"Miruna Florina","year":"2026","journal-title":"Diagnostics"},{"key":"B108","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12967-025-06425-2","article-title":"Machine learning and multi-omics integration: advancing cardiovascular translational research and clinical practice","volume":"23","author":"Lin","year":"2025","journal-title":"J Transl Med"},{"key":"B109","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-019-0535-y","article-title":"Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors","volume":"7","author":"Awadalla","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B110","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00395-024-01046-0","article-title":"Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin","volume":"120","author":"Efentakis","year":"2025","journal-title":"Basic Res Cardiol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000546204","article-title":"Statin and immune-related cardiovascular events in lung cancer patients receiving immune checkpoint inhibitors","volume":"104","author":"Song","year":"2026","journal-title":"Oncology"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3390\/cancers17071169","article-title":"In the era of cardiovascular-kidney-metabolic syndrome in cardio-oncology: from pathogenesis to prevention and therapy","volume":"17","author":"Quagliariello","year":"2025","journal-title":"Cancers Basel"},{"key":"B113","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: cardioOncology primer","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC CardioOncol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1080\/14740338.2021.1906860","article-title":"How can we manage the cardiac toxicity of immune checkpoint inhibitors?","volume":"20","author":"Poto","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"B115","doi-asserted-by":"publisher","first-page":"5403","DOI":"10.3390\/cancers14215403","article-title":"Cardiotoxicity induced by immune checkpoint inhibitors: what a cardio-oncology team should know and do","volume":"14","author":"Zito","year":"2022","journal-title":"Cancers Basel"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1093383","DOI":"10.3389\/fcvm.2023.1093383","article-title":"Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: a single-center experience","volume":"10","author":"Xiao","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1408586","DOI":"10.3389\/fcvm.2024.1408586","article-title":"Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity","volume":"11","author":"Wang","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3389\/fphar.2020.00972","article-title":"How to monitor cardiac complications of immune checkpoint inhibitor therapy","volume":"11","author":"Spallarossa","year":"2020","journal-title":"Front Pharmacol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/ajco.13326","article-title":"Cardiovascular immune-related adverse events: evaluation, diagnosis and management","volume":"16","author":"Liu","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"7737","DOI":"10.3390\/jcm12247737","article-title":"Immune checkpoint inhibitors-associated myocarditis: diagnosis, treatment and current Status on rechallenge","volume":"12","author":"Frascaro","year":"2023","journal-title":"J Clin Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s40959-025-00404-8","article-title":"How should immune checkpoint inhibitor myocarditis be treated?","volume":"11","author":"Badaan","year":"2025","journal-title":"Cardiooncology"},{"key":"B122","doi-asserted-by":"publisher","first-page":"91","DOI":"10.31662\/jmaj.2021-0001","article-title":"Mechanisms and management of immune checkpoint inhibitor-related cardiac adverse events","volume":"4","author":"Kadowaki","year":"2021","journal-title":"JMA J"},{"key":"B123","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ijcard.2021.09.041","article-title":"Cardiotoxicity in cancer immune-checkpoint therapy: mechanisms, clinical evidence, and management strategies","volume":"344","author":"Sun","year":"2021","journal-title":"Int J Cardiol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2147\/CPAA.S369008","article-title":"Neural net modeling of checkpoint inhibitor related myocarditis and steroid response","volume":"14","author":"Stefanovic","year":"2022","journal-title":"Clin Pharmacol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"922782","DOI":"10.3389\/fimmu.2022.922782","article-title":"TNF-\u03b1 Inhibitors and other biologic agents for the treatment of immune checkpoint inhibitor-induced myocarditis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"e001887","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B127","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s11239-025-03146-7","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity: immunology, pathophysiology, diagnosis, and management","volume":"58","author":"Becker","year":"2025","journal-title":"J Thromb Thrombolysis"},{"key":"B128","doi-asserted-by":"publisher","first-page":"579","DOI":"10.4070\/kcj.2021.0089","article-title":"Cardiac toxicities associated with immune checkpoints inhibitors: mechanisms, manifestations and management","volume":"51","author":"Zarifa","year":"2021","journal-title":"Korean Circ J"},{"key":"B129","doi-asserted-by":"publisher","first-page":"ytaf019","DOI":"10.1093\/ehjcr\/ytaf019","article-title":"Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with Abatacept and ruxolitinib: a case report","volume":"9","author":"Wadden","year":"2025","journal-title":"Eur Heart J Case Rep"},{"key":"B130","doi-asserted-by":"publisher","first-page":"105543","DOI":"10.1016\/j.jaccas.2025.105543","article-title":"Successful use of ruxolitinib for steroid-refractory immune checkpoint inhibitor-associated myocarditis","volume":"30","author":"Vockenhuber","year":"2025","journal-title":"JACC Case Rep"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e007530","DOI":"10.1136\/jitc-2023-007530","article-title":"New perspectives in cancer immunotherapy: targeting IL-6 cytokine family","volume":"11","author":"Mar\u00eda Florencia","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B132","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s11912-021-01113-y","article-title":"Interventional strategies in cancer-induced cardiovascular disease","volume":"23","author":"Pushparaji","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B133","doi-asserted-by":"publisher","first-page":"350","DOI":"10.14735\/amko2020350","article-title":"Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors","volume":"33","author":"Mladosievi\u010dov\u00e1","year":"2020","journal-title":"Klin Onkol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"e257357","DOI":"10.1136\/bcr-2023-257357","article-title":"Checkpoint inhibitor myocarditis with preceding immunosuppression and tolerance of sequential anthracycline therapy","volume":"17","author":"Grewal","year":"2024","journal-title":"BMJ Case Rep"},{"key":"B135","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/jcdd12070270","article-title":"Navigating cardiotoxicity in immune checkpoint inhibitors: from diagnosis to long-term management","volume":"12","author":"Nardin","year":"2025","journal-title":"J Cardiovasc Dev Dis"},{"key":"B136","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.3390\/cancers15092637","article-title":"Takotsubo cardiomyopathy in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-summary of included cases","volume":"15","author":"Trontzas","year":"2023","journal-title":"Cancers Basel"},{"key":"B137","doi-asserted-by":"publisher","first-page":"814","DOI":"10.3390\/jcm15020814","article-title":"Immune checkpoint inhibitor-associated myocarditis: risk, diagnosis, and clinical impact","volume":"15","author":"Mauriello","year":"2026","journal-title":"J Clin Med"},{"key":"B138","doi-asserted-by":"publisher","first-page":"e002916","DOI":"10.1136\/jitc-2021-002916","article-title":"Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem","volume":"9","author":"Poels","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B139","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1200\/jco.2017.76.3920","article-title":"Cardiovascular disease in survivors of childhood cancer: insights into epidemiology, pathophysiology, and prevention","volume":"36","author":"Armenian","year":"2018","journal-title":"J Clin Oncol"},{"key":"B140","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/CAD.0000000000001727","article-title":"Nivolumab- and ipilimumab-induced myositis, myasthenia gravis, and myocarditis in a patient with metastatic melanoma","volume":"36","author":"Inan","year":"2025","journal-title":"Anticancer Drugs"},{"key":"B141","doi-asserted-by":"publisher","first-page":"e8968","DOI":"10.1002\/ccr3.8968","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis, myocarditis, and myositis: a case report","volume":"12","author":"Basnet","year":"2024","journal-title":"Clin Case Rep"},{"key":"B142","doi-asserted-by":"publisher","first-page":"9486566","DOI":"10.1155\/crom\/9486566","article-title":"Concurrent nivolumab-induced myocarditis and myasthenia Gravis: a case report","volume":"2026","author":"Gupta","year":"2026","journal-title":"Case Rep Oncol Med"},{"key":"B143","doi-asserted-by":"publisher","first-page":"27","DOI":"10.11477\/mf.1416202554","article-title":"[Clinical features of myasthenia Gravis as an immune-related adverse event]","volume":"76","author":"Suzuki","year":"2024","journal-title":"Brain Nerve"},{"key":"B144","doi-asserted-by":"publisher","first-page":"5583","DOI":"10.1007\/s00432-022-04516-x","article-title":"Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea","volume":"149","author":"Hyun","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1007\/s00415-023-12134-x","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series","volume":"271","author":"Vicino","year":"2024","journal-title":"J Neurol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"884776","DOI":"10.3389\/fphar.2022.884776","article-title":"Immune checkpoint inhibitor-related myositis overlapping with myocarditis: an institutional case series and a systematic review of literature","volume":"13","author":"Nakagomi","year":"2022","journal-title":"Front Pharmacol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"1443004","DOI":"10.1155\/crom\/1443004","article-title":"Myocarditis mimicking takotsubo cardiomyopathy with first dose of neoadjuvant nivolumab-relatlimab","volume":"2025","author":"Rao","year":"2025","journal-title":"Case Rep Oncol Med"},{"key":"B148","doi-asserted-by":"publisher","first-page":"e235265","DOI":"10.1136\/bcr-2020-235265","article-title":"Concomitant myopericarditis and takotsubo syndrome following immune checkpoint inhibitor therapy","volume":"13","author":"Tan","year":"2020","journal-title":"BMJ Case Rep"},{"key":"B149","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3390\/medicina60020224","article-title":"Perimyocarditis associated with immune checkpoint inhibitors: a case report and review of the literature","volume":"60","author":"Shalata","year":"2024","journal-title":"Med Kaunas"},{"key":"B150","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/CJI.0000000000000457","article-title":"Pembrolizumab-Induced acral vasculitis","volume":"46","author":"Yohannan","year":"2023","journal-title":"J Immunother"},{"key":"B151","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","article-title":"Vasculitis associated with immune checkpoint inhibitors-a systematic review","volume":"37","author":"Daxini","year":"2018","journal-title":"Clin Rheumatol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1093\/rheumatology\/keaf172","article-title":"Immune checkpoint inhibitors-induced large vessel vasculitis: clinical characteristics and management from a European multicentre study","volume":"64","author":"Cottu","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"B153","doi-asserted-by":"publisher","first-page":"249","DOI":"10.32074\/1591-951X-N998","article-title":"Immune checkpoint inhibitor therapy in metastatic renal cell carcinoma: tumour response and immune-related renal vasculitis following cytoreductive nephrectomy","volume":"117","author":"Jain","year":"2025","journal-title":"Pathologica"},{"key":"B154","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","article-title":"Smoldering myocarditis following immune checkpoint blockade","volume":"5","author":"Norwood","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B155","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1080\/1750743X.2024.2385286","article-title":"Occult checkpoint inhibitor myocarditis during adjuvant nivolumab plus ipilimumab: a smoldering but severe toxicity","volume":"16","author":"Bafaloukos","year":"2024","journal-title":"Immunotherapy"},{"key":"B156","doi-asserted-by":"publisher","first-page":"e40171","DOI":"10.7759\/cureus.40171","article-title":"Durvalumab-Associated myocarditis initially presenting with sinus bradycardia progressing into complete heart block","volume":"15","author":"Bae","year":"2023","journal-title":"Cureus"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1604989","DOI":"10.3389\/fimmu.2025.1604989","article-title":"The impact of immune checkpoint inhibition on atherosclerosis in cancer patients","volume":"16","author":"Han","year":"2025","journal-title":"Front Immunol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s11936-023-01024-0","article-title":"Immunotherapy-Associated atherosclerosis: a comprehensive review of recent findings and implications for future research","volume":"25","author":"Chan","year":"2023","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"B159","doi-asserted-by":"publisher","first-page":"101840","DOI":"10.1016\/j.jaccas.2023.101840","article-title":"CAR-T Therapy in lymphoma patients with coexisting cardiomyopathy or cardiac lymphomatous involvement","volume":"15","author":"Ng","year":"2023","journal-title":"JACC Case Rep"},{"key":"B160","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/RLU.0000000000005819","article-title":"Epicardial metastases causing coronary artery compression and myocardial infarction on [ 18 F]FDG PET-CT","volume":"50","author":"Wilcox","year":"2025","journal-title":"Clin Nucl Med"},{"key":"B161","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/ehf2.13915","article-title":"Subtle-but-smouldering myocardial injury after immune checkpoint inhibitor treatment accompanied by amyloid deposits","volume":"9","author":"Ida","year":"2022","journal-title":"ESC Heart Fail"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1891563\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:42:35Z","timestamp":1789717355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1891563\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":161,"alternative-id":["10.3389\/fcvm.2026.1891563"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1891563","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1891563"}}